## DT04 Rec'd PCT/PTO 0 9 JUL 2004

## II. Claim Amendments

- 1. (Original) A pharmaceutical composition comprising a polytartrate polymer and at least one pharmaceutically active material characterised in that the composition is capable of releasing the pharmaceutically active material in a pulsatile manner and is obtainable by forming the tablet with a compression force between 10 and 65 kN/cm<sup>2</sup>.
- 2. (Original) The composition according to claim 1 characterised in that the composition is formed at a compression force between 20 and 50 kN/cm<sup>2</sup>.
- 3. (Presently Amended) The composition according to claim 1 or 2 characterised in that the polytartrate polymer forms degradation products that increase the pressure inside the composition.
- 4. (Original) The composition according to claim 3 characterised in that the polytartrate polymer forms during degradation a C1 to C4 alcohol, aldehyde or ester or acetone.
- 5. (Original) The composition according to claim 4 characterised that the polytartrate polymer forms during degradation methanol, ethanol, propanol, isopropanol or acetone.
- 6. (Presently Amended) The composition according to claims 1-to-5 characterised in that the polytartrate polymer is selected from the group of polycondensates of dimethyl tartrate, diethyl tartrate, diisopropyl tartrate or copolymers thereof and 2,3-O-alkylidenetartaric acid derivatives.
- 7. (Original) The composition according to claim 6 characterised in that the polytartrate polymer is 2 '3'-(1', 4'-diethyl) L- tartryl poly (2, 3-O-isopropylidene) L tartrate.
- 8. (Presently Amended) The composition according to any of the claims 1 to 7 characterised in that the polytartrate polymer has a glass transition temperature that is greater than 40°C.
- 9. (Presently Amended) The composition according to any of the claims 1 to 8 characterised in that the pharmaceutically active material is selected from one or more of antigens, antibodies or pharmaceutical substances.
- 10. (Original) The composition according to claim 9 characterised in that the pharmaceutically active material is a GnRH agonist.

- 11. (Original) The composition according to claim 10 characterised in that the pharmaceutically active material is buserelin.
- 12. (Original) The composition according to claim 11 characterised in that the pharmaceutically active material is azagly nafarelin.
- 13. (Presently Amended) The composition according to any of the claims 1 to 12 characterised in that the composition additionally comprises one or more of pharmaceutically acceptable excipients or adjuvants.
- 14. (Presently Amended) Process for the preparation of a polytartrate composition according to claims 1 to 13 involving the steps of
  - a) mixing an effective amount of a pharmaceutically active material with the polytartrate polymer,
  - b) shaping the mixture by a tabletting equipment to form compressed tablets by applying a compression force between 10 and 65kN/cm<sup>2</sup>.
- 15. (Original) according to claim 14 characterised in that the pharmaceutically active material and the polytartrate polymer are mixed in a powdered form.
- 16. (Presently Amended) The process according to any of the claims 14 or 15 characterised in that the mixture is sieved and optionally additional tabletting excipients are added to the mixture.
- 17. (New) A method of administering a pulsatile pharmaceutically active material to a body comprising the step of administering the composition of Claim 1 to the body.
- 18. (New) The method of Claim 17 wherein the body is selected from an animal body and a human body.
- 19. (New) A method of administering a pharmaceutically active material to a body comprising the steps of:
  administering a composition of Claim 1 to the body wherein the pharmaceutically is released in at least two phases comprising an initial burst and a second burst.
- 20. (New) The method of Claim 19 wherein the initial burst and the second burst is separated by a lag phase.